Latest news

Research3

Establishment and inaugural meeting of the Clinical and Scientific Advisory Board

Synapse Electroceutical Limited are delighted to announce the establishment of a Clinical and Scientific Advisory Board comprised of eminent experts in the fields of Wound Healing research, science, clinical practice, pain management and health economics.

Read this article

Synapse CEO announcement

Synapse Electroceutical today announced that the Board of Directors has appointed Andy Boyes as Interim Chief Executive Officer. John Gildersleeve will assume the role of Business Development Director and will continue to serve as an executive director on the Board.

Read this article
Become a Distributor

Andy Boyes appointed as Non-Executive Director to Synapse Electroceutical Limited

Synapse Electroceutical Limited is delighted to announce the appointment of Andy Boyes to the Board. Andy has enjoyed a successful, 32 year career at Smith & Nephew, the FTSE 100 medical technology business engaged in developing, manufacturing, marketing and selling medical devices in the Advanced Wound Management and Advanced Surgical Devices sectors with sales in excess of £4 billion. Andy is passionate
about the wound care sector and helping improve the lives of patients suffering with debilitating complex wounds and since leaving Smith & Nephew has focussed on providing Board level support and strategic direction in the sector.

Read this article

Other articles



Regulatory and IP

All Synapse electroceutical products are designed and manufactured to conform with the highest standards of quality and safety.

All our products adhere to the quality standards dictated by the International Organisation for Standardization (ISO), Medical Device Directive (MDD), Medical Device Classification and carry the Conformité Européenne (CE) marking. In 2007 Synapse Micro-Current Ltd achieved ISO 9001 Quality Management Systems and ISO 13485 accreditation for the design and manufacture of medical devices for sport and medical applications. In addition, Synapse has over 50 patents already granted and several pending in key territories of the world as well as a number of registered trademarks.

Synapse Electroceutical medical products are officially certified as Class IIA devices under the medical device directive 93/42/EEC.

Accel-Heal® carries the CE mark having been tested and approved by Notified Body 0120 Accel-Heal® is manufactured to ISO 13485:2016 for the design and manufacture of medical devices.

All Synapse Electroceutical products carry the CE marking.

For a comprehensive document covering hazards, contra-indications and warranty please visit this link.

The Synapse Electroceutical Accel-heal® unit is classified as Class IIA medical devices, having been tested and approved by Notified Body 0120 at meeting the standards of the Medical Devices Directive and the ISO 13485 management system.

Therapeutic Goods Administration (TGA) Approval for Accel-Heal in Australia.

Information for Clinicians

Accel-Heal product shot